Finance / United States
If you would like to subscribe to Corporate Financing Week and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Corporate Financing Week please click on the trial link below.
Bristol Bids US$5.2bn For ImClone
July 2008 | M&A News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Corporate Financing Week and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Corporate Financing Week please click on the trial link below.
In a deal worth up to US$5.2bn, US pharmaceutical giant Bristol-Myers Squibb has offered to buy ImClone Systems for US$60 a share. In an attempt to gain greater control of joint-venture cancer drug Erbitux, Bristol has offered an approximately 30% premium on ImClone's closing share price on July 30. Investors, however, seem to expect more. Morning trading on July 31 saw ImClone stock jump by 39% to reach US$64.20 a share, fuelling speculation that the company will attract a higher offer.